key: cord-0901992-sxl49cs3 authors: Moustsen-Helms, I. R.; Emborg, H.-D.; Nielsen, J.; Nielsen, K. F.; Krause, T. G.; Molbak, K.; Moeller, K. L.; Berthelsen, A.-S. N.; Valentiner-Branth, P. title: Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers - a Danish cohort study date: 2021-03-09 journal: nan DOI: 10.1101/2021.03.08.21252200 sha: e9b30868861615ce19811d6a3a4a545c16ae8126 doc_id: 901992 cord_uid: sxl49cs3 Abstract Background At the end of 2020, Denmark launched an immunization program against SARS-CoV-2. The Danish health authorities prioritized persons currently living in long-term care facilities (LTCF residents) and frontline healthcare workers (HCW) as the first receivers of vaccination. Here we present preliminary population based vaccine effectiveness (VE) estimates in these two target groups. Methods The study was designed as a retrospective registry- and population-based observational cohort study including all LTCF residents and all HWC. The outcome was a polymerase chain reaction confirmed SARS-CoV-2, and VE was estimated for different periods following first and second dose. We used Poisson and Cox regressions to estimate respectively crude and calendar time-adjusted VE for the BNT162b2 mRNA Covid-19 Vaccine from Pfizer/BioNTech with 95% confidence intervals (CI) for vaccinated versus unvaccinated. Results A total of 39,040 LTCF residents (median age at first dose; 84 years, Interquartile range (IQR): 77-90) and 331,039 HCW (median age at first dose; 47 years, IQR: 36-57) were included. Among LTCF residents, 95.2% and 86.0% received first and second dose from 27 December 2020 until 18 February 2021, for HWC the proportion was 27.8% and 24.4%. During a median follow-up of 53 days , there were 488 and 5,663 confirmed SARS-CoV-2 cases in the unvaccinated groups, whereas there were 57 and 52 in LTCF residents and HCW within the first 7 days after the second dose and 27 and 10 cases beyond seven days of second dose. No protective effect was observed for LTCF residents after first dose. In HCW, VE was 17% (95% CI; 4-28) in the > 14 days after first dose (before second dose). Furthermore, the VE in LTCF residents at day 0-7 of second dose was 52% (95% CI; 27-69) and 46% (95% CI; 28-59) in HCW. Beyond seven days of second dose, VE increased to 64% (95% CI; 14-84) and 90% (95% CI; 82-95) in the two groups, respectively. Conclusion The results were promising regarding the VE both within and beyond seven days of second vaccination with the BNT162b2 mRNA Covid-19 Vaccine currently used in many countries to help mitigate the global SARS-CoV-2 pandemic. Impact of the research: So far, observational studies of the real-word effectiveness of the mRNA Vaccine BNT162b2 has been limited to the period after the administration of the first dose. This is the first report to date to present vaccine effectiveness (VE) estimates after the second BNT162b2 mRNA Covid-19 Vaccine. We estimated a VE of 52% and 46% in LTCF residents and HCW within seven days, which increased to 64% and 90% in the two groups respectively beyond seven days of immunization. These findings supports maintaining a two-dose schedule of the BNT162b2 mRNA Covid-19 Vaccine. In Denmark, the national Covid-19 vaccination strategy aims at protecting those at risk of severe outcomes of a SARS-CoV-2 infection resulting in hospitalization or death, and secure key societal functions such as the healthcare system 1 . Hence, residents in long-term care facilities (LTCF) and front-line healthcare workers (HCW) were target groups prioritized for vaccination, when the vaccination program started on 27 December 2020. On 16 December 2020 (week 51), a nationwide partial lock down was initiated following widespread community transmission of SARS-CoV-2. In week 53 when the immunization program started, there were several reports of Covid-19 outbreaks in LTCF and the positive percentage for tested LTCF residents was 4.21% ( Figure 1a) while it was 2.21% for HCW (Figure 1b) . The aim was to estimate VE for first and second dose of the BNT162b2 mRNA vaccine in two separate cohorts: 1) all LTCF residents, and 2) all HCW, both with no history of SARS-CoV-2, using data from Danish registries. National Patient Registry 6 . LTCF residents was identified by linking the Civil Registry System to addresses for LTCF by the Danish Health and Medicines Authority 1 7 . Information on persons working in healthcare was retrieved from The Danish Agency for Labour Market and Recruitment (described in 8 9 ). We used retrospective population-based cohort studies to estimate VE after first and second vaccine dose. The two cohorts included all LTCF residents and all HCW either living in Denmark at start of vaccination (27 December 2020) or immigrating before the end of study on 18 February 2021. Persons with PCR confirmed SARS-CoV-2 before start of the study were excluded. The cohort was followed from the beginning of the immunization program on 27 December 2020 and until date of positive SARS-CoV-2 test, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 1) . During the study period, 91,865 HCW received first dose and 80,839 received second dose of the BNT162b2 mRNA vaccine (Table 1) . Days between first and second dose for LTCF residents and HCW were 24 (IQR; 20-52) and 25 (IQR 20-51), respectively. More than 99% of the vaccines administered to LTCF residents were BNT162b2 mRNA, which was the case for 89% in HCW (on 18 February 2021). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2021. For LTCF residents, we found an adjusted VE of 52% (95% CI; 27-69) within 0-7 days after second dose, which increased to 64% (95% CI; 14-84) from 7 days after second dose. In HCW, we observed the same pattern; an adjusted VE of 46% (95% CI; 28-59) in day 0-7 that increased to 90% (95% CI; 82-95) after 7 days following the second dose. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.08.21252200 doi: medRxiv preprint It is very reassuring that we find high VEs in a real-world setting where one cohort had a median age of 84 years at time of first vaccination The findings for the LTCF cohort are encouraging as this group comprises the most vulnerable part of the population and immunosenescence in the elderly population is generally a challenge for vaccines 12 . When the vaccination program was initiated, the national Covid-19 incidence was at the highest level since the beginning of the pandemic and the proportion of LTCF residents tested positive for Covid-19 was increasing (Figure 1a) . However, it is worth noting that a partial lockdown had been initiated to reduce circulation of Covid-19 a few weeks before the immunization program started. These interventions Figure 1a and 1b) . Therefore, the rate of infection decreased during the study period. The high vaccination coverage achieved in LTCF may have decreased risk of infection within the facilities, as they are relatively closed settings. The main strengths of this study was that the two population-based cohorts of LTCF residents and HCW were followed using national, high quality information on vaccination status and laboratory SARS-CoV-2 positive samples. Due to the situation at nursing homes, there was increased focus on testing in LTCF. Furthermore, there was a national testing strategy, where HCW were offered weekly PCR-testing. Therefore, we believe that our study includes close to all cases of SARS-CoV-2. Further, our cases included both asymptomatic and symptomatic disease based on all conducted laboratory PCR SARS-CoV-2 tests, nationally. Test results from rapid antigen tests and PCR tests at private test centers were not available. However, they constitute a small fraction of test conducted in the study cohorts. Antigen tests were only offered in limited extent to some HCWs. The adjusted VE for the HCW cohort presented here, is similar to the vaccine efficacy of 95% (95% CI; 90-98) reported by Polack et al. 10 in a phase III trial including 43,448 participants with a median age of 52 at time of vaccination. Another interesting finding that aligned with the phase III trial was the unaffected VE estimates after adjustment for age, sex and comorbid conditions, which may be explained by these populations assumingly being relatively young and healthy at time of vaccination 10 . Expectedly, the estimated VE among LTCF residents was lower (VE; 64%, 95% CI; 14-84) than the VE reported by Polack . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.08.21252200 doi: medRxiv preprint and colleagues. This could be explained by the higher vulnerability and age distribution in our cohort, a median age of 84 years in LTCF residents compared to 52 years among the trial participants. It is also evident from studies of influenza vaccines, that vaccines are less effective in the elderly 12 We observed no or low VE after just one dose. However, it is important to note that there was a short interval (median 24 and 25 days) between first and second dose, and therefore it is unlikely that the full impact of a single dose can be extrapolated from our findings. Our findings compared to findings from studies including only first dose corroborate that a two-dose schedule to obtain maximum benefit of the BNT162b2 mRNA vaccine is important. Nonetheless, studies with a longer follow-up between first and second dose are warranted in order to explore potential advantages of a strategy with a postponed second dose. The cohorts included in this study are two different segments of the Danish population. The findings on VE in LTCF residents may apply to other vulnerable elderly populations with similar conditions. This is the first study to report VE in LTCF residents, an age group not included in previous studies, where the populations were relatively young. The estimated VEs for HCW might be more generalizable as this population in many ways is comparable with other subpopulations. HCW have special knowledge on importance of protective equipment, why the VE in this group may not extrapolate to all populations in the same age groups. On the other hand, HCW have an increased risk of infection, through patient contacts, that may be higher than in the general population. All in all, the present study confirms, from the field, that two doses of BNT162b2 mRNA vaccine offers protection against SARS-CoV-2 infections in two critical groups, albeit with a better VE among HCW with a median age of 47 years than among a vulnerable population of long-term-care facility residents with a median age of 84 years. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.08.21252200 doi: medRxiv preprint Authors declare no conflicts of interest. Retningslinje for håndtering af vaccination mod COVID-19 [red. Guidelines for handling vaccination against Covid-19]: The National Board of Health The Danish Civil Registration System The Central Person Registry: The Ministry for Economic Affairs and the Interior The Danish Microbiology Database (MiBa) The Danish vaccination register The Danish National Patient Register Residents in nursing homes DREAM vejledning version 44 v2 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Assessment report Comirnaty Common name: COVID-19 mRNA vaccine (nucleosidemodified) 2020 Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of 'real-world' vaccination outcomes from Israel Legend to Figure 1a and 1b: Weekly number of laboratory confirmed SARS-CoV2, number of tests and proportion of positive tests distributed on test weeks for LTCF residents and HCW in Denmark from week 49 The authors are grateful to The Danish Health Data Authority for their help in defining the populationcohorts. Special thanks to Mette Lange, Line Hansen, and Joanna Phermchai-Nielsen. We would also like to thank the Department of Data Integration and Analysis at Statens Serum Institut for excellent data management.